• HOME>
  • Investor Relations>
  • IR News>
  • Sumitomo Dainippon Pharma Announces Partnership with Zuellig Pharma on its Carbapenem Antibiotic Meropenem for Five Countries of South-East Asia and Hong Kong

IR News

Jun. 09, 2017Print(PDF/110KB)Licensing

Sumitomo Dainippon Pharma Announces Partnership with Zuellig Pharma on its Carbapenem Antibiotic Meropenem for Five Countries of South-East Asia and Hong Kong

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) announced today that it has concluded an agreement with Zuellig Pharma relating to distribution and sales of meropenem, a carbapenem antibiotic, originally created by Sumitomo Dainippon Pharma in five countries of South-east Asia (Vietnam, Thailand, Singapore, Philippines, Malaysia) and Hong Kong.

Under the terms of the agreement, Sumitomo Dainippon Pharma will supply the finished products of meropenem to Zuellig Pharma and Zuellig Pharma will distribute and sell meropenem in five countries of South-east Asia and Hong Kong.

Sumitomo Dainippon Pharma has over twenty years'experience and knowhow in marketing and business alliances related to meropenem in four countries in East Asia (Japan, China, Korea, and Taiwan), while Zuellig Pharma boasts an extensive track record of distributing and promoting pharmaceutical products in South-east Asia. Through a close cooperative framework between the two companies, we aim to contribute our services to the critical care of as many severe infectious disease patients as possible in five South-east Asian countries and Hong Kong.

Sumitomo Dainippon Pharma already announced that it has entered into an agreement with AstraZeneca to conduct meropenem business in five South-east Asian countries and Hong Kong, on December 26, 2016.

 

<Reference information>

【About meropenem】
Meropenem is a carbapenem antibiotic created by Sumitomo Dainippon Pharma and developed as an antibiotic preparation for injection, which was launched in Japan in 1995. This drug is widely used for various types of moderate to severe infectious diseases caused by gram-positive / gram-negative bacteria. This medicine is sold by Sumitomo Dainippon Pharma and Pfizer, out-licensing company, in more than 100 countries.

【About Zuellig Pharma】
Zuellig Pharma has been successfully serving the Asian healthcare market since 1922. Today we are the region's leading health care services provider. Zuellig Pharma is present in 13 countries and offers a range of innovative solutions for clients, customers, practitioners and patients. Zuellig Pharma employs 10,000 people and serves more than 300,000 doctors, hospitals, pharmacies and clinics across the region, helping to make healthcare more accessible across Asia.